GlassScriptPhysician profile
Jordan Lidsky-Everson
NPI 1508570367
$2,717.04
in general payments reported to CMS, 2019-2025
29 companies · $1,827 in 2025
The $1,827 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $417 · 2024: $473 · 2025: $1,827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,245 · Education: $472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,245.15 |
| Education | $471.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $460.35 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| E.R. Squibb & Sons, L.L.C. | $319.56 | 2023-2025 | Opdivo, Onureg, Opdualag |
| Celgene Corporation | $258.21 | 2023-2025 | Reblozyl, Opdualag, Breyanzi |
| Janssen Biotech, INC. | $158.15 | 2025 | Rybrevant |
| Daiichi Sankyo INC. | $150.67 | 2023-2024 | Enhertu, Injectafer |
| Astellas Pharma US INC | $126.95 | 2025 | Vyloy, Padcev |
| Sobi, INC | $124.18 | 2025 | |
| Novartis Pharmaceuticals Corporation | $112.41 | 2023-2025 | |
| Coherus Oncology, INC. | $109.49 | 2024-2025 | Loqtorzi |
| Merck Sharp & Dohme LLC | $104.86 | 2023-2025 | Keytruda, Lynparza |
| Pfizer INC. | $86.53 | 2024-2025 | |
| Stemline Therapeutics INC. | $77.02 | 2024 | Orserdu |
| Jazz Pharmaceuticals INC. | $73.01 | 2025 | |
| Emd Serono, INC. | $62.63 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $60.07 | 2025 | Tagrisso, Imfinzi |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $50.21 | 2025 | |
| Genzyme Corporation | $50.10 | 2025 | |
| Geron Corporation | $48.47 | 2025 | Rytelo |
| Caris Mpi, INC. | $31.09 | 2025 | Mi Cancer Seek |
| Pharmaessentia USA Corporation | $29.69 | 2025 | Besremi |
| Genentech USA, INC. | $29.48 | 2025 | Itovebi |
| Puma Biotechnology, INC. | $28.41 | 2025 | |
| Sumitomo Pharma America, INC. | $28.11 | 2025 | Orgovyx |
| Glaxosmithkline, LLC. | $27.75 | 2025 | Ojjaara |
| Eisai INC. | $27.66 | 2025 | |
| Springworks Therapeutics, INC. | $26.82 | 2025 | Ogsiveo |
| Taiho Oncology, INC. | $25.66 | 2025 | |
| Accord Healthcare, INC. | $15.01 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.49 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Lidsky-Everson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.